Industry Briefs: Mar. 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Galapagos has received EUR 3.5 million ($4.59 million) in milestone payments in its osteoarthritis alliance with Servier. Read More

JHP Pharmaceuticals has added a second product to its previously announced multiyear contract manufacturing agreement with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent. Read More

Lonza and Eclipse Therapeutics have formed a development and manufacturing agreement. Read More

Mylan continues to pursue damages and and its injunction against Sunovion’s Brovana in an ongoing litigation. Mylan believes a federal district court erred in its partial summary judgment decision. Read More

Pfenex and DNA2.0 have formed a collaboration on protein expression technology. Read More

People News

Albany Molecular Research (AMRI) has named Tom McGrath as director of quality for aseptic services, and Chris Phillips has been appointed to the role of senior director of operations, at AMRI’s Burlington, Massachusetts site. Read More

Alkermes has appointed Mark Stejbach as chief commercial officer. Read More

AstraZeneca has announced the retirement of Louis Schweitzer from the board as chairman and as a director, effective Sept. 1, 2012. Read More

Novartis has named Brian McNamara division head of Novartis OTC. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here